Depakin Chrono

Quick links to important sections

Depakin Chrono

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Depakin Chrono

Property Description
Active Ingredient Valproate semisodium (a compound of Valproic Acid and Sodium Valproate)
Form Prolonged-release film-coated tablet
Pharmacological Class Antiepileptic Drug (AED), Mood Stabilizer
General Purpose Neurological stabilization by regulating brain activity
Origin Synthetic (Fatty acid derivative)

Depakin Chrono is a prescription-only medicine that functions as both an Antiepileptic Drug (AED) and a systemic Mood Stabilizer. Its primary classification as an AED is based on its capability to manage conditions stemming from neuronal hyperexcitability, a class designation that is clinically recognized for its broad application in managing chronic neurological conditions. The core active compound is Valproic Acid, which is a synthetic chemical entity and a fatty acid derivative.

Composition and the Meaning of 'Chrono'

The medication's fundamental composition relies on Valproate semisodium, a stable combination product that synthesizes Valproic Acid and Sodium Valproate in a specific ratio. This compound is administered in a specialized prolonged-release film-coated tablet formulation for oral administration. The inclusion of the term "Chrono" emphasizes the sustained-release delivery profile, which is engineered to maintain consistent blood concentrations of the active agent throughout the day. This controlled delivery mechanism is a key differentiating factor from immediate-release valproate formulations.

What is the General Purpose of Valproate Semisodium?

The general purpose of this therapy is to promote systemic neurological stability by calming overactive nerve signals. The medication achieves this by increasing the effectiveness of gamma-aminobutyric acid (GABA), the brain's main natural inhibitory neurotransmitter. Research confirms that valproate is a first-line treatment for certain seizure types due to its efficacy in controlling neuronal activity. The resulting benefit is the reliable reduction of neuronal instability and the stabilization of nerve cell excitability, which serves as the foundation for the drug's therapeutic applications in various patient groups.

Regulatory References

  1. EMA Valproate referral page

What side effects are possible with Depakin Chrono?

Possible Side Effects and Safety Information

The official safety profile for valproate semisodium, the active ingredient in Depakin Chrono, outlines adverse reactions categorized by frequency and the body system affected, according to regulatory documents from authorities like the EMA and FDA. This information defines the medicine's documented safety characteristics.


Frequency and System-Organ Classifications

Side effects are classified based on their observed incidence:

Classification Adverse Reaction (Examples) Associated System-Organ Class
Very Common ( ge 1/10) Tremor, Nausea Nervous System; Gastrointestinal
Common ( ge 1/100 to <1/10) Somnolence, Weight gain, Alopecia Nervous System; Metabolism; Skin

Gastrointestinal effects and somnolence are often observed more frequently during the initiation of treatment. Conversely, weight gain is commonly associated with long-term exposure. The safety profile involves several systems, including the Hepatobiliary System (elevated liver enzymes) and the Blood and Lymphatic System (e.g., thrombocytopenia).


Serious Adverse Reactions and Restrictions

Regulatory labeling highlights specific serious adverse reactions. These include a risk of hepatic failure (severe liver damage), which is particularly noted in children under three years old, and potentially fatal pancreatitis (inflammation of the pancreas). Severe dermatological reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented risks. For women of childbearing potential, there is an explicit, high risk of teratogenicity (congenital malformations) and developmental delays.

The medication is contraindicated in individuals with acute or chronic hepatitis, or those with known urea cycle disorders, due to the risk of hyperammonemic encephalopathy.

Overdose and Emergency Response

Overdose and When to Seek Help

Valproate semisodium overdose, including the prolonged-release formulation (Depakin Chrono), is associated with a severe clinical presentation defined by regulatory authorities. The most common manifestations are profound CNS depression, ranging from somnolence and lethargy to coma and respiratory depression. Other documented signs include vomiting, abdominal pain, and cardiovascular irregularities such as hypotension and tachycardia.

The official regulatory profile classifies massive overdose as potentially life-threatening due to serious systemic derangements. These complications include metabolic acidosis, hyperammonemic encephalopathy, and cerebral edema. For any suspected ingestion, regulators mandate that individuals seek immediate medical attention/evaluation. Urgent medical help is specifically required if symptoms like unexplained lethargy, persistent vomiting, or new abdominal pain occur, as these can signal severe, escalating risk.

Management focuses on specialized supportive treatment, as no specific antidote is known. Procedures documented in regulatory guidance may include gastric lavage, activated charcoal, hemodialysis for massive levels, and the targeted use of intravenous Levocarnitine to manage hyperammonemia. Furthermore, the risk of fatal hepatotoxicity is a critical population-specific consideration documented in children under the age of two years.

Therapeutic Uses of Depakin Chrono

What Depakin Chrono Treats: Main Uses and Benefits

Depakin Chrono, a prolonged-release formulation of valproate, is generally used to help manage symptoms associated with certain neurological and psychiatric conditions, which include relevant therapeutic domains. The medication is considered relevant in conditions characterized by periods of heightened symptoms, which may involve epilepsy and acute manic episodes associated with bipolar disorder.

The medication is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that may become intense or disruptive. It provides supportive relief when symptoms become temporarily overwhelming, contributing to easing the overall symptom load.

“This support assists with maintaining functional stability during symptomatic periods.”


Quick Fact: Managing Episodic Symptoms

Depakin Chrono is commonly used when short-term symptom stabilization is important, assisting with maintaining functional stability in conditions involving episodic or fluctuating manifestations.

Regulatory References

  1. European Medicines Agency therapeutic domains

Eligibility and Restrictions for Use

Who Can and Cannot Use Depakin Chrono?

This section explains the official population eligibility and non-eligibility rules for Depakin Chrono (Valproate semisodium), as documented in regulatory prescribing information.


Contraindicated Populations

Depakin Chrono must not be used in patients with acute or chronic hepatitis or a history of severe liver disease. It is also strictly contraindicated for individuals diagnosed with Hepatic Porphyria or Urea Cycle Disorders (UCDs), and those with known mitochondrial disorders (e.g., POLG mutations).

Age and Reproductive Status

The medicine is contraindicated in pregnant women unless no suitable alternative treatment exists. For Women of Childbearing Potential, use is highly restricted and permitted only when the strict conditions of the Pregnancy Prevention Programme are met. For the pediatric population, the prolonged-release tablet is not suitable for children under 6 years old due to risks related to formulation suitability, and use in children under 2 years old carries the highest risk of fatal hepatotoxicity. For patients with Renal Impairment, use is allowed but may require a dosage adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Valproate semisodium focuses on interactions that alter plasma exposure and those that pose an additive systemic risk. All information is based strictly on government-issued prescribing documents.


Documented Interaction Restrictions

Substance Category Restriction / Outcome Statement
Carbapenem Antibiotics Co-administration should be avoided due to a rapid and severe reduction in Valproate plasma levels, leading to loss of control.
Salicylates (Aspirin) Restricted in children under 3 years of age due to the officially documented risk of heightened liver toxicity.
Alcoholic Beverages Should not be consumed during treatment.

Pharmacokinetic and Pharmacodynamic Effects

Valproate is documented to interact with numerous other medicinal products:

  • Exposure Alteration: Hepatic enzyme-inducing drugs (e.g., Phenytoin, Carbamazepine) increase Valproate clearance, leading to lower exposure. Conversely, enzyme-inhibiting drugs (e.g., Felbamate) decrease Valproate clearance, increasing its plasma concentration.
  • Increased Levels of Co-administered Drugs: Valproate inhibits the metabolism of other Antiepileptic Drugs, such as Phenobarbital and Lamotrigine, resulting in increased concentrations of those drugs.
  • Additive Risk: Co-administration with Topiramate is associated with a risk of Hyperammonemia and encephalopathy. Combination with other CNS depressants (e.g., Benzodiazepines) may result in increased sedation.

Mechanism of Action

Depakin Chrono, which contains the active substance valproate, functions through multiple complementary mechanisms that regulate signaling within the central nervous system. This multifaceted action affects signaling dynamics across multiple neuronal pathways.

Modulating Inhibitory Neurotransmission

Depakin Chrono modulates key pathways associated with inhibitory signaling by increasing the availability of GABA (gamma-aminobutyric acid), the brain's primary inhibitory neurotransmitter. This mechanism is achieved by engaging enzymes that inhibit GABA breakdown and promote its synthesis, thereby modifying the activity of pathways associated with heightened physiological responses.

Stabilizing Neuronal Excitability

The drug acts within domains involving ion-channel-mediated signaling by affecting voltage-gated ion channels. Specifically, it can reduce high-frequency neuronal firing by blocking voltage-gated sodium channels and modulating T-type calcium channels. The interaction with membrane mechanisms results in an altered neuronal refractory period and decreased action potential firing frequency.

Influencing Gene Expression Pathways

Valproate engages mechanisms that regulate underlying, long-term cellular processes through the inhibition of histone deacetylases (HDACs). This enzymatic action modifies molecular steps that shape systemic physiological outcomes by altering the expression of various genes. This mechanism influences the expression of genes involved in cellular homeostasis and synaptic signaling.

Dosage and Administration Information

The administration of Depakin Chrono, a prolonged-release tablet containing valproate semisodium, follows specific, label-based instructions for its oral use. The formulation's administration is strictly by the oral route, and the tablet must be swallowed whole without being crushed or chewed to ensure the sustained-release mechanism functions as intended. The prolonged-release design allows the total daily dose to be administered as one or two divided doses; a single daily dose may be appropriate for patients whose condition is well-controlled.

Treatment begins with a specified initial daily dose, such as 10 to 15 mg/kg per day for adults in epilepsy management, or 1000 mg daily for acute manic episodes. This starting dose is followed by a gradual increase (titration) over approximately one to two weeks to achieve the optimal maintenance dose, which typically ranges from 20 to 30 mg/kg per day. Dosage adjustments are primarily determined by the individual patient's clinical response.

Population Key Dosing Rule
Adults (Maintenance) 20 to 30 mg/kg per day, up to 60 mg/kg per day maximum.
Pediatric (over 20 kg) Usual dose is 20 to 30 mg/kg per day.
Older Adults Dosage is determined based on symptomatic control.

Official instructions specify that the medicine should preferably be administered during meals. For achieving specific prescribed doses, the scored tablet may be broken in half, but no further physical manipulation is permitted.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides a summary of the clinical studies that have been conducted on the compound (valproate semisodium). It describes the scope of the research and the main measures that were evaluated.


Phase I and II Studies: Safety and Initial Parameters

Phase I and II studies focused primarily on assessing the compound's safety profile, pharmacological metrics, and participant response in a small number of volunteers.

Evaluation of Action and Initial Effect

Studies investigated the potential action of the compound. These initial studies examined the compound's properties for use in chronic pain scenarios. The studies also evaluated different dose levels to determine the maximum evaluated dose and the initial observed effect on key pain indicators.

  • Key Findings: The research reported common and serious adverse events for various dose levels. The maximum dose level that was evaluated was 20 mg.

Combination Therapy

Studies evaluated whether the compound, when administered alongside an established standard-of-care medication, affected measures of patient outcomes. These studies focused on patients in moderate-to-severe phases of the condition.

  • Key Findings: Studies observed the participant response to the combination. Research is ongoing to evaluate the compound in patient subgroups with severe symptoms.

Phase III Clinical Trials: Broader Patient Groups

Phase III trials enrolled a larger, more diverse population of participants to compare the compound's findings against a placebo over a longer period.

Primary Outcome Measures

The primary focus of the Phase III program was to evaluate the compound's influence on various patient-reported pain scales and functional assessments. The findings from the trials were compared to the placebo group.

  • Evaluation of Pain Data: Studies examined the magnitude and duration of observed pain changes. One study examined the relationship between observed pain changes and participant-reported functional scores.
  • Quality of Life Assessment: Researchers investigated whether the compound affected participants' quality of life as measured by validated questionnaires (e.g., SF-36).

Key Studies & References

  1. Bipolar disorder: assessment and management - NICE Guideline CG185
  2. NCT06714448 | A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia | ClinicalTrials.gov

Frequently Asked Questions (FAQ)

Common questions about Depakin Chrono (FAQ)


Q: Can Depakin Chrono interact with hormonal contraceptives or birth control pills?

A: According to official product information, the active ingredient in Depakin Chrono is generally not documented to reduce the effectiveness of hormonal contraceptives by interfering with the liver enzymes responsible for processing birth control hormones. Potential interactions are described in official documents, and consistent treatment is monitored by a healthcare provider.


Q: Can men use Depakin Chrono if they plan on fathering children?

A: Regulatory agencies have issued precautionary advice regarding the use of valproate by men who plan on fathering children. Recent data suggests a potential small increased risk of harm to children if the medicine is used around the time of conception. Official guidance states that the use of effective contraception by men and their partners is required as part of the risk management program.


Q: Are there any specific dietary restrictions to consider while on Depakin Chrono?

A: Official warnings state that the consumption of alcoholic beverages is advised against during treatment with Depakin Chrono. Beyond this, regulatory documents generally do not list specific food or beverage restrictions. The medicine is, however, strictly contraindicated in people with Urea Cycle Disorders, a rare medical condition related to the body's processing of protein.


Q: Are there official warnings about combining Depakin Chrono with other psychiatric medications?

A: Regulatory documents describe an increased risk of side effects when Depakin Chrono is combined with other medicines that affect the central nervous system (CNS). Specifically, there is an additive risk of increased sedation or drowsiness when taken with other CNS depressants, which includes some psychiatric medications like benzodiazepines.


Q: Does the effectiveness of Depakin Chrono change if consumed with or without food?

A: Official administration instructions state that the medicine should preferably be taken during meals. To ensure consistent control of the condition and to maintain stable levels of the medication in the body, it is generally advised to stick to the same administration method (with or without food) each day.


Q: What happens if a dose of Depakin Chrono is accidentally missed?

A: Guidance for a missed dose is included in the patient information leaflet. Generally, if a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. If that is the case, the missed dose should be skipped entirely. Official guidance specifies that taking two doses at the same time to catch up is not advised.


Q: Can Depakin Chrono be taken with common supplements like multivitamins?

A: Regulatory knowledge indicates that the medicine may interfere with the body's levels of certain nutrients, including vitamins like folate and substances like carnitine. This is due to how the drug is metabolized in the body. If blood levels are affected, a healthcare professional assesses whether nutritional supplementation is necessary for the patient.


Q: Is Depakin Chrono described as safe to take before driving or operating machinery?

A: Official warnings state that the medicine may cause side effects such as drowsiness or sedation, which can impair the ability to drive or operate complex machinery. Official documentation advises that patients understand how the medicine affects them personally before engaging in activities that require full mental alertness.


Q: Can Depakin Chrono be used in children or adolescents?

A: The medicine is generally approved for use in both children (over 6 years old for the prolonged-release tablet form) and adolescents, following specific dosing guidelines determined by weight. However, official information highlights that use in children under 2 years old carries the highest documented risk of fatal liver toxicity.


Q: Can Depakin Chrono be used for managing chronic headaches or migraines?

A: Valproate, the active ingredient in Depakin Chrono, is officially licensed in several regions for the prophylactic (preventive) treatment of migraine headaches. This means it is used to reduce the frequency and severity of migraines.


Q: Is Depakin Chrono a benzodiazepine?

A: No. Depakin Chrono is officially classified as an Antiepileptic Drug (AED) and a Mood Stabilizer. The active ingredient is a fatty acid derivative and belongs to a different chemical class than benzodiazepines.


Q: What kind of monitoring or blood tests are generally associated with taking Depakin Chrono?

A: Monitoring generally involves regular testing of certain parameters as determined by a healthcare provider, such as liver function tests, platelet counts, and, in some cases, checks of the plasma concentrations of valproic acid. This monitoring is required as part of the medicine's official safety precautions.


Q: Is Depakin Chrono commonly prescribed for conditions other than epilepsy or bipolar disorder?

A: The medicine is officially indicated for the treatment of epilepsy and manic episodes associated with bipolar disorder. Valproate is also licensed in several regions for the prevention of migraine headaches, which is an additional approved indication.


Q: Is there any research about Depakin Chrono affecting vitamin or mineral levels in the body?

A: Official information describes that the medicine may interfere with the body's levels of certain nutrients. This includes vitamins like folate and substances like carnitine, which may be depleted due to the drug's metabolism. This potential effect sometimes leads to consideration of supplementation for certain patients.


Q: Why is the medicine sometimes described with a black box warning?

A: The medicine carries a U.S. regulatory Black Box Warning because of the frequency and severity of specific serious risks. These documented risks include hepatotoxicity (liver damage), pancreatitis (pancreas inflammation), and the high risk of congenital malformations and developmental delay when used during pregnancy.


Q: Is Depakin Chrono considered a controlled substance?

A: The legal classification of the medicine varies by region. In major markets like the U.S. and U.K., it is typically classified as a standard prescription-only medicine. However, in some countries (such as Brazil), the compound is legally categorized as a controlled substance due to its neurological effects.


Q: How is the medicine eliminated from the body?

A: Pharmacokinetic data in the official product information explains that valproate is primarily processed through metabolism in the liver. It is then eliminated from the body through subsequent excretion in the urine.


Q: Is the medicine available in generic form?

A: Yes, the active ingredient in Depakin Chrono, which is valproate semisodium, is widely available as a generic medication under various chemical names (like divalproex sodium). Generic versions must meet the same quality standards as the brand name product.


Q: Can using Depakin Chrono cause tremors or shaking?

A: Yes, tremor (shaking) is listed as a very common adverse reaction in the medicine's official safety information. This means that a significant percentage of patients in clinical studies reported experiencing it.


Q: Are there long-term effects associated with Depakin Chrono use?

A: Regulatory documents describe several effects associated with long-term exposure, including a common risk of weight gain. Official documentation mentions that serious events like pancreatitis are documented risks, and potential nutritional deficiencies are a factor that may be assessed over extended periods of use.


Q: Are there different brand names for the same active ingredient as Depakin Chrono?

A: Yes, the active ingredient in Depakin Chrono (valproate semisodium) is also marketed globally under several other brand names, depending on the country and formulation. Examples include Depakote, Epilim, and Convulex.


Q: What is the typical age range of people who are prescribed Depakin Chrono?

A: Official prescribing information provides specific usage guidelines and dosing restrictions that span a wide age range. This includes instructions for children over the age of 6 (for the tablet form) and guidelines for its use throughout adulthood and into older age.


Q: Can Depakin Chrono affect hormone levels in women with polycystic ovary syndrome (PCOS)?

A: Studies have examined a possible association between valproate and the development of features consistent with Polycystic Ovary Syndrome (PCOS) in some women. Official guidance advises that patients should be monitored for associated changes, such as unexpected weight gain or menstrual irregularity.


Q: What is the general duration of treatment for conditions treated by Depakin Chrono?

A: For the long-term management of chronic conditions such as epilepsy or bipolar disorder, the official patient information often indicates that treatment with the active ingredient is typically intended to be continued for an extended period, often described as many years.


Q: Can Depakin Chrono cause changes in mood or personality?

A: The official safety profile includes psychiatric side effects. In rare cases, these medicines can be associated with or worsen symptoms of depression or cause changes in mood. Official guidance advises that patients should be monitored for any new or worsening psychiatric symptoms.

How should Depakin Chrono be stored and disposed of?

Storage and Disposal Requirements

Depakin Chrono tablets must be stored according to strict regulatory guidelines to maintain the integrity of the prolonged-release formulation.

Storage Condition Requirement
Temperature Store below 25 C (77 F); Do not refrigerate or freeze.
Protection Keep in the original container to protect from moisture and light.
Child Safety Mandatory to keep out of the sight and reach of children.

Expired or unused tablets must be handled as pharmaceutical waste. Do not dispose of the medicine by flushing it down the toilet or placing it in household trash. Official instructions require disposal via a local drug take-back program or by returning the product to a pharmacy for secure, regulated handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Depakin Chrono found in:

A-Z Index: